IMMX, CMRX &TXMD : Strong Buy Forecast 🚀👍💪🌈
3 Biotech Penny Stocks to Add to Your Market Crash Watchlist
Immix Biopharma Inc. (NASDAQ: IMMX)
TherapeuticsMD Inc. (NASDAQ: TXMD)
Chimeric Inc. (NASDAQ: CMRX)
Immix Biopharma Inc. (NASDAQ: IMMX)
One of the bigger gainers of the day is IMMX stock. At EOD, shares of IMMX stock shot up by over 30%, with a 5% gain in after hours trading. And, in the past five day period, shares of IMMX have climbed by more than 50%.
While we do see many gains with penny stocks without news, today, Immix made an exciting announcement in premarket trading. The company stated that its IMX-110 drug demonstrated improved survival over the current approved drug, Trabectedin. It states that IMX-110 is part of what is expected to be a $6.5 billion market by 2030.
“We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies. We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked-off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab.”
The CEO of Immix Bio, Ilya Rachman
Right now, there is quite a lot of bullish sentiment with biotech penny stocks. And, as a clinical stage biopharmaceutical company, Immix is at the center of this. While it is highly volatile IMMX stock could be worth adding to your list of penny stocks to watch.
TherapeuticsMD Inc. (NASDAQ: TXMD)
Another gainer of the day on May 20th is TXMD stock, which shot up by over 35%. In the past month, shares of TXMD stock have fallen by around 74%, which makes this gain much more substantial.
Next Up
NEXT UP
Typical monthly payment for US home up 42% in a year
Typical monthly payment for US home up 42% in a year
Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market
J Dylan May 20, 2022 Updated May 20, 2022 0
SMS
Save
3 Hot Biotech Penny Stocks to Add to Your Watchlist With the Market Down
Recently, biotech penny stocks have seen heightened bullish sentiment. Today, the emphasis on biotech stocks comes as the Monkeypox virus is seeing a resurgence in certain areas around the world. Today, the WHO confirmed 80 cases of the virus in 11 countries. And since then, investors have begun looking for biotech stocks that may be able to benefit.
[Read More] Penny Stocks To Buy Now? Hot Monkeypox Stocks To Watch Today
Around The Web
Sponsored by Revcontent
You'll Never Think About Solar Panels Again After Seeing This (Watch)
You'll Never Think About Solar Panels Again After Seeing This (Watch)
Smart Investors Zone
This Weird Method Can Restore Your Vision Naturally (Watch)
This Weird Method Can Restore Your Vision Naturally (Watch)
Smart Life Reports
This Video Will Soon Be Banned. Watch Before It's Deleted
This Video Will Soon Be Banned. Watch Before It's Deleted
Secrets Revealed
In addition to this, we are also seeing heightened volatility with penny stocks and blue chips. This means that it is more important than ever to stay on your toes. Understanding what your trading strategy is and how you can best execute it is crucial in these market conditions.
If you are thinking about getting into penny stocks, then make sure to do your research first. There is a lot going on in the stock market, so researching and understanding all you can about penny stocks is essential to your success. With this in mind, let’s take a look at three biotech penny stocks to add to your watchlist right now.
3 Biotech Penny Stocks to Add to Your Market Crash Watchlist
Immix Biopharma Inc. (NASDAQ: IMMX)
TherapeuticsMD Inc. (NASDAQ: TXMD)
Chimeric Inc. (NASDAQ: CMRX)
Immix Biopharma Inc. (NASDAQ: IMMX)
One of the bigger gainers of the day is IMMX stock. At EOD, shares of IMMX stock shot up by over 30%, with a 5% gain in after hours trading. And, in the past five day period, shares of IMMX have climbed by more than 50%.
While we do see many gains with penny stocks without news, today, Immix made an exciting announcement in premarket trading. The company stated that its IMX-110 drug demonstrated improved survival over the current approved drug, Trabectedin. It states that IMX-110 is part of what is expected to be a $6.5 billion market by 2030.
“We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies. We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked-off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab.”
The CEO of Immix Bio, Ilya Rachman
Right now, there is quite a lot of bullish sentiment with biotech penny stocks. And, as a clinical stage biopharmaceutical company, Immix is at the center of this. While it is highly volatile IMMX stock could be worth adding to your list of penny stocks to watch.
Penny_Stocks_to_Watch_Immix
TherapeuticsMD Inc. (NASDAQ: TXMD)
Another gainer of the day on May 20th is TXMD stock, which shot up by over 35%. In the past month, shares of TXMD stock have fallen by around 74%, which makes this gain much more substantial.
[Read More] Penny Stocks To Buy? Warren Buffett’s Bitcoin Bet, 3 Stocks To Watch
Today, the company announced that it received FDA approval for its Supplemental New Drug Application for Annovera. With this approval, the company will be able to produce 7,000 additional rings for the supply chain, which will be made available to customers by the second and third quarter of this year.
“Today’s approval is an important milestone as it will allow us to more efficiently scale, manufacture, and consistently supply ANNOVERA to meet the increasing demand by women who want procedure-free, long-lasting reversible birth control.”
The CEO of TherapeuticsMD, Hugh O’Dowd
Back in 2018, Annovera was approved by the FDA as a long-lasting, reversible, procedure-free birth control product. And since then, the company has worked hard to commercialize it as much as possible. With that in mind, do you think TXMD is a worthwhile add to your penny stocks watchlist or not?
Chimeric Inc. (NASDAQ: CMRX)
With an over 6.8% gain at EOD on May 20th, CMRX stock is another penny stock that investors are watching right now. In the past five days, we’ve seen a very steady gain with CMRX stock, pushing up by more than 20%, which is no small feat. And, this comes after a six month drop of over 60%.
The main reason for today’s gain with CMRX stock comes as fears surrounding an increase in Monkey Pox cases, are driving up biotech stocks. This includes Chimeric, which recently announced a deal with Emergent, to offer exclusive rights for its smallpox oral antiviral product known as Tembexa.
And, given that Monkey Pox is a smallpox derivative virus, we see the major correlation between the two. With this new virus situation, there is a large demand increase for this vaccine. And while the fears that are comparing this virus to Covid-19 are somewhat unwarranted, there is a lot to consider. With this in mind, does CMRX deserve a spot on your buy list or not?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
$Immix Biopharma, Inc.(IMMX)$
Immix Biopharma Inc. (NASDAQ: IMMX) was up 30% after the biopharmaceutical firm pioneering Tissue-Specific Therapeutics targeting immune-dysregulated and oncology diseases announced positive preliminary trial data showing that after one treatment cycle, its lead candidate IMX-110 had 75% survival compared to 0% survival for FDA-approved drug Trabectedin that is sold as YONDELIS.
Trading Data
On Friday, IMMX stock gained 30.06% to $2.12 with more than 111.65 million shares, compared to its average volume of 2 million shares. The stock moved within a range of $2.0700 – 2.8700 after opening trade at $2.49.
Key Details
The company compared IMX-110 against approved drugs from STS treatment in the study. IMX-110 was given at 2.0 mg/kg while Trabectedin was administered as per Meco et al. (2003) monotherapy arm.